AnaptysBio Announces Appointment of Daniel Faga to Board of Directors

SAN DIEGO, Nov. 29, 2021 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced the appointment of Mr. Daniel Faga to the company’s Board of Directors.

Click here to view original post

ADVERTISEMENT — Advertise With Biotech Networks